Advertisement

Chromatographia

, Volume 29, Issue 1–2, pp 44–50 | Cite as

Determination of azidothymidine and its degradation product thymine in pharmaceutical dosage forms by HPLC and HPTLC densitometry

  • H. Tománková
  • J. Šabartová
Originals

Summary

HPTLC densitometry and HPLC are considered for the determination of azidothymidine and its degradation product thymine in pharmaceutical dosage forms. In HPTLC the substances were separated on silica gel with fluorescence indicator in methanol-chloroform (10∶90) and methanol-chloroform (15∶85) systems. Absorbance measurement (detection of reflectance) of the separated substances was carried outin situ at 268 nm using four-level calibration (external standard, linear regression function) in the concentration range of 25–100 ng thymine/spot and using single-level calibration (external standard) at the concentration of 100 ng azidothymidine/spot. HPLC was carried out using RP-18 stationary phase and methanol+aqueous 0.03 mol/l KH2PO4 (18+82, v/v) as the mobile phase. The temperature was 50°C and the detection wavelength 266 nm. The detection limit of thymidine was 0.05%. The concentration range for azidothymidine was 0.5–1.5 mg/ml and for thymine 1–40 μg/ml (for an injection volume of 10 μl). The results were evaluated by linear regression analysis.

Key Words

Column liquid chromatography Thin layer chromatography Azidothymidine Thymine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    J. P. Horowitz, J. Chua, M. Noet, J. Org. Chem.,29, 2076 (1964).Google Scholar
  2. [2]
    H. Mitsuya, K. J. Weinhold, P. A. Furman, M. H. Stclair, S. N. Lehrman, R. C. Gallo, D. Bolognesi, D. W. Barry, S. Broder, Proc. Natl. Acad. Sci. USA82, 7096 (1985).PubMedGoogle Scholar
  3. [3]
    W. P. Parks, E. S. Parks, J. Acquired Immune Deficiency Syndromes,1, 125 (1988).Google Scholar
  4. [4]
    E. D. Bashaw, M. A. Amantea, Amer. J. Hospital Pharmacy,45, 2532 (1988).Google Scholar
  5. [5]
    M. A. Skinner, T. J. Matthews, J. Acquired Immune Deficiency Syndrome1, 162 (1988).Google Scholar
  6. [6]
    V. Herbert, S. Hirschman, JAMA,260, 3586 (1988).Google Scholar
  7. [7]
    I. V. D. Weller, A. Mills, British Medical J.,297, 1608 (1988).Google Scholar
  8. [8]
    S. E. Keller, S. J. Schleifer, J. A. Bartlett, R. L. Johnson, JA MA,260, 3586 (1988).Google Scholar
  9. [9]
    H. D. Langtry, D. M. Campoli-Richards, Drugs,37, 40 (1989).Google Scholar
  10. [10]
    P. A. Cload, J. Infection18, Suppl. 1, 15 (1989).CrossRefGoogle Scholar
  11. [11]
    I. Williams, G. Gabriel, H. Cohen, P. Williams, R. S. Tedde, S. Machin, I. V. D. Weller, J. Infection, Suppl.1, 23 (1989).CrossRefGoogle Scholar
  12. [12]
    J. M. Yeo, J. Infection18, Suppl. 1, 93 (1989).CrossRefGoogle Scholar
  13. [13]
    L. E. Mathes, G. Muschik, L. Demby, P. Polas, D. W. Melini, H. J. Issaq, R. Sams, J. Chromatogr.,432, 346 (1988).PubMedGoogle Scholar
  14. [14]
    J. D. Unadkat, S. S. Crosby, J. P. Wang, C. C. Hertel, J. Chromatogr.,430, 420 (1988).PubMedGoogle Scholar
  15. [15]
    M. A. Hedaya, R. J. Sawchuk, Clin. Chem.,34, 1565 (1988).PubMedGoogle Scholar
  16. [16]
    S. S. Good, D. J. Reynolds, P. de Miranda, J. Chromatogr.431, 123 (1988).PubMedGoogle Scholar
  17. [17]
    M. R. Blum, S. H. T. Liao, S. S. Good, P. de Miranda, Amer. J. Med.,85, Suppl. 2A, 189 (1988).Google Scholar
  18. [18]
    W. J. M. Underberg, U. K. Underberg-Chitoe, O. Bekers, L. Meenhorst, J. H. Beijnen, Internat. J. Pharmaceutics,50, 175 (1989).CrossRefGoogle Scholar
  19. [19]
    Analytical Procedures — Azidothymidin tablets, Lachema Czechoslovakia, 1989.Google Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1990

Authors and Affiliations

  • H. Tománková
    • 1
  • J. Šabartová
    • 1
  1. 1.State Institute for Drug ControlPragueCzechoslovakia

Personalised recommendations